Alembic Pharmaceuticals net profit dropped 23% YoY to ₹138.4 crore in Q3 FY25 from ₹180.4 crore in the same quarter of last ...

The contract is an EPC contract and encompasses the design, engineering, manufacturing, supply, erection, commissioning, and civil works.

The deal is aimed at improving operational efficiency, expanding capabilities, and fuel innovation in the maritime sector.

As part of the contract, debentures shall have a tenure of 3,651 days (approx. 10 years) and shall be listed on the Wholesale ...

However, the company stated that its revenue from operations registered a growth of 66.90% to ₹534.70 Crore in Q3FY25.

The revenue increased by 8% YoY to ₹11,995 crores against ₹11,066 crores in Q3 FY24 due to strong demand in the market.

At the operating level, EBITDA declined by 8% YoY to ₹177.1 crore from ₹192.4 crore in the same quarter last year.

In January 2025, passive funds also saw strong inflows, with marginal price depletion.

At 3.0%, the US consumer inflation is a full 100 bps above the Fed target of 2.0%, reducing further rate cut hopes ...

After the core inflation fell to 3.58% in December 2024, it has bounced back to 3.70% in January 2025. This is due to the ...

On the sell side, the fund cut positions in Infosys and Sun Pharma. The fund’s top 5 stock picks for January 2025 based on ...

Reliance Industries Q2 profit reported a net profit rose 7% to ₹18,540 crore in Q3 FY25 from ₹17,265 crore in Q3 FY24.